Bioavailability of curcumin: problems and promises
- PMID: 17999464
- DOI: 10.1021/mp700113r
Bioavailability of curcumin: problems and promises
Abstract
Curcumin, a polyphenolic compound derived from dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Phase I clinical trials have shown that curcumin is safe even at high doses (12 g/day) in humans but exhibit poor bioavailability. Major reasons contributing to the low plasma and tissue levels of curcumin appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination. To improve the bioavailability of curcumin, numerous approaches have been undertaken. These approaches involve, first, the use of adjuvant like piperine that interferes with glucuronidation; second, the use of liposomal curcumin; third, curcumin nanoparticles; fourth, the use of curcumin phospholipid complex; and fifth, the use of structural analogues of curcumin (e.g., EF-24). The latter has been reported to have a rapid absorption with a peak plasma half-life. Despite the lower bioavailability, therapeutic efficacy of curcumin against various human diseases, including cancer, cardiovascular diseases, diabetes, arthritis, neurological diseases and Crohn's disease, has been documented. Enhanced bioavailability of curcumin in the near future is likely to bring this promising natural product to the forefront of therapeutic agents for treatment of human disease.
Similar articles
-
Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer.Eur J Pharm Sci. 2009 Jun 28;37(3-4):223-30. doi: 10.1016/j.ejps.2009.02.019. Epub 2009 Mar 10. Eur J Pharm Sci. 2009. PMID: 19491009
-
Systemic delivery of curcumin: 21st century solutions for an ancient conundrum.Curr Drug Discov Technol. 2009 Sep;6(3):192-9. doi: 10.2174/157016309789054933. Epub 2009 Sep 1. Curr Drug Discov Technol. 2009. PMID: 19496751 Review.
-
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature.Biochem Pharmacol. 2008 Dec 1;76(11):1590-611. doi: 10.1016/j.bcp.2008.08.008. Epub 2008 Aug 19. Biochem Pharmacol. 2008. PMID: 18775680 Review.
-
Curcumin as "Curecumin": from kitchen to clinic.Biochem Pharmacol. 2008 Feb 15;75(4):787-809. doi: 10.1016/j.bcp.2007.08.016. Epub 2007 Aug 19. Biochem Pharmacol. 2008. PMID: 17900536 Review.
-
Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.Planta Med. 1998 May;64(4):353-6. doi: 10.1055/s-2006-957450. Planta Med. 1998. PMID: 9619120 Clinical Trial.
Cited by
-
Alginate and Chitosan-Based Delivery Systems for Improving the Bioavailability and Therapeutic Efficacy of Curcumin.Pharmaceutics. 2024 Mar 19;16(3):423. doi: 10.3390/pharmaceutics16030423. Pharmaceutics. 2024. PMID: 38543316 Free PMC article. Review.
-
Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment.Antioxidants (Basel). 2024 Mar 8;13(3):331. doi: 10.3390/antiox13030331. Antioxidants (Basel). 2024. PMID: 38539864 Free PMC article. Review.
-
Molecular Dynamics and In Vitro Studies Elucidating the Tunable Features of Reconfigurable Nanodiscs for Guiding the Optimal Design of Curcumin Formulation.Bioengineering (Basel). 2024 Feb 29;11(3):245. doi: 10.3390/bioengineering11030245. Bioengineering (Basel). 2024. PMID: 38534519 Free PMC article.
-
Immunomodulatory effects of curcumin on macrophage polarization in rheumatoid arthritis.Front Pharmacol. 2024 Feb 28;15:1369337. doi: 10.3389/fphar.2024.1369337. eCollection 2024. Front Pharmacol. 2024. PMID: 38487171 Free PMC article. Review.
-
Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.EXCLI J. 2024 Feb 7;23:212-263. doi: 10.17179/excli2023-6868. eCollection 2024. EXCLI J. 2024. PMID: 38487088 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
